107836-75-9

Basic information

• Product Name: 4,6-dichloronicotinoyl chloride
• Synonyms: 4,6-dichloronicotinoyl chloride
• CAS NO: 107836-75-9
• Molecular Formula: C₆H₂Cl₃NO
• Molecular Weight: 210.44518
• Mol File: 107836-75-9.mol

Chemical Properties

• Boiling Point: 271.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.582±0.06 g/cm3(Predicted)
• PKA: -1.76±0.10(Predicted)
• CAS DataBase Reference: 4,6-dichloronicotinoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloronicotinoyl chloride(107836-75-9)
• EPA Substance Registry System: 4,6-dichloronicotinoyl chloride(107836-75-9)

Safety Data

• Hazardous Substances Data: 107836-75-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,6-dichloronicotinoyl chloride is used as a synthetic intermediate for the development of pharmaceutical drugs. Its reactivity allows for the creation of various drug compounds that can address a range of health conditions.
Used in Agricultural Industry:
In the agricultural sector, 4,6-dichloronicotinoyl chloride is used as a precursor in the production of insecticides and herbicides. Its role in synthesizing these agrochemicals helps protect crops from pests and weeds, ensuring higher yields and crop quality.
It is crucial to follow proper safety precautions when working with 4,6-dichloronicotinoyl chloride due to its reactive nature and potential hazards.

Upstream product

• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 73027-79-9 4,6-dichloro-nicotinic acid 

Downstream Products

• 70593-57-6 4,6-dichloro-nicotinamide 
• 1092062-74-2 6-chloro-3-methyl-1H-pyrazolo[4,3-c]pyridine 
• 887573-44-6 1-(4,6-dichloropyridin-3-yl)ethan-1-one 
• 1092063-12-1 6-chloro-3-methyl-1-p-tolyl-1H-pyrazolo[4,3-c]pyridine 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 29051-45-4 4-methyl-6-phenyl-nicotinic acid 
• 1417792-29-0 C₁₅H₁₅NO₂ 
• 862170-53-4 (2,6-dichloro-3-pyridinyl)[4-(methyloxy)phenyl]methanone 
• 1001084-23-6 C₂₁H₁₇ClN₂O₃ 

Relevant articles and documents

Novel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and SNAr reactions of a dihalogenated compound

A new route towards the synthesis of a series of 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones in moderate to good yields is reported. The strategy involves the preparation of a 3,7-dihalogenated compound that undergoes differential functionalization using palladium-catalyzed cross-coupling and SNAr reactions.

HETEROARYL SULFONAMIDE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS

The present invention relates to a compound represented by formula (I) or a salt thereof which has excellent insecticidal, acaricidal and/or nematicidal activity, exhibits excellent safety, and can be advantageously synthesized industrially, and also relates to a formulation for controlling harmful organisms which contains the same. In formula (I), Ar1 represents a 5- to 6-membered heteroaryl ring, R1 represents a halogeno group, a substituted or unsubstituted C1 to C6 alkyl group, or the like, n represents an integer of any one of 1 to 3, in the case of n being 2 or 3, two R1 may be linked together to form, in combination with the carbon atoms to which they are bonded, a substituted or unsubstituted 5- or 6-membered ring, R2 represents a C1 to C6 haloalkyl group, or the like, G represents an oxygen atom or a sulfur atom, each of R3 and R4 independently represents a hydrogen atom, a substituted or unsubstituted C1 to C6 alkyl group, or the like, and Ar2 represents a substituted or unsubstituted C6 to C10 aryl group or a substituted or unsubstituted 5- or 6-membered heteroaryl group.

Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27

GPR27 belongs, with GPR85 and GPR173, to a small subfamily of three receptors called “Super-Conserved Receptors Expressed in the Brain” (SREB). It has been postulated to participate in key physiological processes such as neuronal plasticity, energy metabolism, and pancreatic β-cell insulin secretion and regulation. Recently, we reported the first selective GPR27 agonist, 2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I, pEC50 6.34, Emax 100%). Here, we describe the synthesis and structure-activity relationships of a series of new derivatives and analogs of I. All products were evaluated for their ability to activate GPR27 in an arrestin recruitment assay. As a result, agonists were identified with a broad range of efficacies including partial and full agonists, showing higher efficacies than the lead compound I. The most potent agonist was 4-chloro-2,5-difluoro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7y, pEC50 6.85, Emax 37%), and the agonists with higher efficacies were 4-chloro-2-methyl-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7p, pEC50 6.04, Emax 123%), and 2-bromo-4-chloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7r, pEC50 5.99, Emax 123%). Docking studies predicted the putative binding site and interactions of agonist 7p with GPR27. Selected potent agonists were found to be soluble and devoid of cellular toxicity within the range of their pharmacological activity. Therefore, they represent important new tools to further characterize the (patho)physiological roles of GPR27.

AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-2

NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors

The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay.

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

GPR120 agonists have therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds displaying unexpected high CNS penetration. Increased MDCK efflux was utilized to identify compounds such as 33 with lower CNS penetration, and activity in oral glucose tolerance studies was demonstrated. Differential activity was observed in GPR120 null and wild-type mice indicating that this effect operates through a mechanism involving GPR120 agonism.

ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.

QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE

There is provided compounds of formula I, wherein X1 to X4, R1 to R4, Y1, Y2 and L are as defined in the description, and pharmaceutically-acceptable salts thereof, which may be useful in the treatment and/or prophylaxis of autoimmune diseases, inflammatory (e.g. chronic inflammatory) diseases and/or other diseases that may benefit from production of ROS (reactive oxygen species) by a NADPH oxidase complex.